KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Non-Current Liabilities: 2010-2025

Historic Other Non-Current Liabilities for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to $5.0 million.

  • Nektar Therapeutics' Other Non-Current Liabilities fell 27.30% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 27.30%. This contributed to the annual value of $7.2 million for FY2024, which is 56.22% up from last year.
  • Per Nektar Therapeutics' latest filing, its Other Non-Current Liabilities stood at $5.0 million for Q3 2025, which was down 10.84% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Other Non-Current Liabilities ranged from a high of $27.7 million in Q4 2021 and a low of $2.1 million during Q2 2022.
  • In the last 3 years, Nektar Therapeutics' Other Non-Current Liabilities had a median value of $5.6 million in 2025 and averaged $5.9 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Other Non-Current Liabilities surged by 549.86% in 2021, and later plummeted by 85.72% in 2022.
  • Nektar Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $27.7 million in 2021, then tumbled by 72.77% to $7.6 million in 2022, then crashed by 38.62% to $4.6 million in 2023, then spiked by 56.22% to $7.2 million in 2024, then dropped by 27.30% to $5.0 million in 2025.
  • Its last three reported values are $5.0 million in Q3 2025, $5.6 million for Q2 2025, and $6.8 million during Q1 2025.